Is Ernexa Therapeutics Inc (ERNA) a risky stock?
As of July 27, 2026, Clavix grades Ernexa Therapeutics Inc (ERNA) D+ for risk, a composite score of 44 out of 100 on an A+ to F scale, which puts ERNA in the "elevated risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 27, 2026. Clavix regrades every trading day.
ERNA price, last 3 months
ERNA's daily closes over the past three months. Clavix reads risk from the fundamentals and news behind the price, not the line itself.
The five risk dimensions behind ERNA's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how ERNA scores on each, as of July 27, 2026.
What's moving ERNA's risk right now
Company-specific signals Clavix flags behind ERNA's current grade, drawn from recent news and filings as of July 27, 2026.
Ernexa's lead drug ERNA-101 has finished GMP manufacturing, a key step before its planned Q3 2026 IND filing for first-in-human trials. The milestone brings a near-term catalyst closer, though Ernexa will still need more capital to fund clinical work.
Recent data of Ernexa consists of head-to-head stock comparisons with peers and the launch of a CEO Corner commentary series. There is no new clinical, financial, or competitive development in these pieces.
Recent ERNA news
The latest headlines Clavix ingested for Ernexa Therapeutics Inc, newest first. These feed the news-sentiment dimension of ERNA's grade.
-
Ernexa Therapeutics published a CEO Corner piece discussing how ERNA-101, designed to convert immunologically 'cold' tumors into immune-recognized targets, could support next-generation combination cancer therapies. The article is a thought-leadership piece rather than a substantive business update.
-
Ernexa Therapeutics announced plans for a first-in-human Phase 1 trial of ERNA-101 in Q4 2026, reporting 100% long-term survival and complete tumor clearance in preclinical ovarian cancer models using its off-the-shelf iMSC platform.
-
Ernexa Therapeutics shares jumped 30% after an independent contract research organization replicated earlier preclinical findings for its lead cell therapy candidate ERNA-101, confirming complete tumor clearance and extended survival in a larger ovarian cancer study.
What a D+ grade means
On the Clavix A+ to F scale, ERNA's composite of 44 falls in the D band (35–49), read as "elevated risk." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell ERNA or any security. Grades are risk indicators, not predictions of return. Data may be delayed.